Table 1 Potential benefits of treatment identified in different sources
Gabapentin for neuropathic pain | Quetiapine for bipolar depression | |
|---|---|---|
Previous trials and systematic reviews | (1) Mood (2) Pain intensity (3) Quality of life (4) Satisfaction with treatment (5) Sleep disturbance (6) Use of other pain medications | (1) Anxiety (2) Depression (3) Functioning (4) Quality of life (5) Sleep |
FDA prescribing informationa | “NEURONTIN is indicated for: Postherpetic neuralgia in adults” | “SEROQUEL is indicated as monotherapy for the acute treatment of depressive episodes associated with bipolar disorder.” |
Compendia (DRUGDEX)a | “Relief of pain associated with postherpetic neuralgia is indicative of a therapeutic response to gabapentin.” | “Regular- and extended-release quetiapine is indicated for the acute treatment of depressive episodes associated with bipolar disorder…” |
PatientsLikeMe | “Neuropathic pain” | “Bipolar disorder” |
Core outcomes sets (COS) | Pain 11-point (0–10) numerical rating scale of pain intensity Usage of rescue analgesics Categorical rating of pain intensity (none, mild, moderate, severe) in circumstances in which numerical ratings may be problematic Physical functioning (either one of two measures) Multidimensional Pain Inventory Interference Scale Brief Pain Inventory interference items Emotional functioning (at least one of two measures) Beck Depression Inventory Profile of Mood States Participant ratings of global improvement and satisfaction with treatment Patient Global Impression of Change Symptoms and adverse events Passive capture of spontaneously reported adverse events and symptoms and use of open-ended prompts Participant disposition Detailed information regarding participant recruitment and progress through the trial, including all information specified in the CONSORT guidelines [23] | No relevant core outcome set |